Tavapadon (Juvmo) for Parkinson's Disease

Tavapadon (Juvmo – Abbvie), an oral nonergot partial dopamine agonist, has been approved by the FDA for treatment of Parkinson's disease (PD).

Publication Details

Journal
The medical letter on drugs and therapeutics/The medical letter
Published
2026-10-28
DOI
https://doi.org/10.58347/tml.2026.1767b
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tavapadon (Juvmo) for Parkinson's Disease

3 links
The medical letter on drugs and therapeutics/The medical letter
Parkinson's Disease Mechanisms and Treatments
article

Tavapadon (Juvmo) for Parkinson's Disease

article en

Abstract

Tavapadon (Juvmo – Abbvie), an oral nonergot partial dopamine agonist, has been approved by the FDA for treatment of Parkinson's disease (PD).

The medical letter on drugs and therapeutics/The medical letterVol. 68(1767)
Good health and well-being
Openalex Percentile: Top 14%
Parkinson's Disease Mechanisms and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Tavapadon (Juvmo) for Parkinson's Disease · The medical letter on drugs and therapeutics/The medical letter (2026) | TGRS Research Map | TGRS